EUR/USD 1.15025
-0.246%
Gold 4035.10
-0.390%
Oil 78.718
-5.318%
USD/JPY 156.969
-1.387%
GBP/USD 1.34235
-0.390%
GBP/JPY 210.712
-1.771%
Browse More
  • English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
According to a Reuters White House correspondent, the U.S. Department of Energy is also expected to host an event this Friday focusing on workforce development. The event will include representatives from all 14 accredited mining colleges in the U.S., aiming to raise public awareness of mining as a career path and emphasize the need for more students to enter the field.On August 4th, Senate Minority Leader Chuck Schumer wrote: "Trumps illegal war on Iran is a gift to his oil allies who supported his campaign with campaign funds and promised huge profits. This has proven to be the only promise he has actually kept. Meanwhile, Americans are paying over $4 a gallon for gasoline and are burdened by ever-increasing energy costs."The memo shows that Citigroup (CN) has hired Rohan Sen from Bank of America to lead its technology services banking business coverage.On August 4th, the head of Amazons (AMZN.O) cloud business stated that customers are shifting from using the companys services to train AI models to integrating these models into their own business processes, driving increased demand for inference computing. Matt Garman, CEO of Amazon Web Services, said on Monday, "Were still seeing some companies using large training clusters, but as these models become more popular and powerful, more and more companies are integrating this inference capability into their workloads." He stated that the potential of the artificial intelligence business is "enormous," and the company will continue to increase capital expenditures to meet the growing demand. As the worlds largest provider of computing power and data services leasing, Amazon said last week that it expects capital expenditures to reach $220 billion by 2026, up from its previous forecast of $200 billion. The increased spending reflects rising prices for storage chips and other components needed for data centers.Boeing (BA.N) shares rose 5.6% after the Boeing 737 Max 7 received certification from the U.S. Federal Aviation Administration (FAA).

Pfizer seeks U.S. approval for a reformulated Omicron vaccination booster

Aria Thomas

Aug 23, 2022 10:55

5.png


Pfizer Inc (NYSE:PFE) and its German partner BioNTech stated on Monday that they had submitted an application for U.S. approval of a COVID-19 vaccine booster modified to target the Omicron form and that doses would be available for distribution immediately following regulatory clearance.


The request to the Food and Drug Administration was for a bivalent vaccine containing both the widespread BA.4/BA.5 variants and the original coronavirus strain. It is intended for persons older than 12 years.


Pfizer indicated that it was set to fulfill a $3.2 billion contract with the United States government for 105 million doses, including Omicron-tailored injections, in September.


Albert Bourla, the chief executive officer of Pfizer, said in a statement, "We are prepared to immediately begin distribution of the bivalent Omicron BA.4/BA.5 boosters if approved."


Countries, including the United Kingdom, the United States, and members of the European Union, have prepared fall vaccination campaigns to protect against future outbreaks. The United Kingdom was the first nation to approve a bivalent immunization developed by Moderna last week (NASDAQ:MRNA).


Bourla announced on Twitter that Pfizer plans to finalize its submission to the European Medicines Agency in the next few days (NYSE:TWTR).


Similar to how annual changes to influenza vaccinations are handled, the FDA requested in June that COVID-19 vaccine producers modify injections to target the two sub variants and noted that it would not require new human testing studies for approval.


According to mid- to late-stage studies, Pfizer's older BA.1-tailored vaccine demonstrated a superior immune response against the subvariant.


This month, it is anticipated that a study of the BA.4/BA.5 vaccine in adults aged 12 and older would commence.

Suggestion